|Healthcare Review: Herbalife, Zynex, Sequenom, Cancer Genetics, Anacor Pharmaceuticals|
|By Staff and Wire Reports|
|Monday, 21 July 2014 14:01|
Shares of Herbalife ($HLF -6.2%) tank on a 2x surge in volume ahead of tomorrow's webcast at 10:00 am EDT by Bill Ackman's Pershing Square Capital Management. Mr. Ackman et al. will be presenting their findings from their investigation into the company's Nutrition Clubs.I nterested persons may access the presentation via www.HerbalifePyramidScheme.com.
Zynex (OTCQB:ZYXI -13.8%) hires Brian Alleman as CFO replacing Anthony Scalese. He joins the firm from Alleman & Associates where he was Managing Director.
Sequenom (SQNM +3.6%) subsidiary Sequenom Laboratories plans to launch its VisibiliT laboratory-developed test (LDT) next month in ex. U.S. markets. The test utilizes chromosomal material from chromosomes 18 and 21 in combination with maternal age and fetal fraction to generate a personalized risk score for fetal trisomies such as Down syndrome and Edwards syndrome. The test is performed using a maternal blood sample and applies to a single gestation pregnancy considered to be at average risk.
Cancer Genetics (CGIX +3.8%) acquires privately-held Gentris Corp., a provider of genomic testing and pharmacogenomics services to biotech/pharma companies. Gentris will add $5M - 6M in top line revenue and contract backlog of over $18M. Financial terms are not disclosed.
Anacor Pharmaceuticals (NASDAQ:ANAC) enters into an exclusive agreement with Sandoz (NYSE:NVS) to commercialize Anacor's Kerydin (tavaborole) topical solution in the U.S. Sandoz's PharmaDerm division will be responsible for the sales and marketing of the recently-FDA cleared antifungal for the treatment of onychomycosis of the toenails.